Alteon, Inc.

Composition-of-matter patent issued covering A.G.E. Crosslink Breakers

Published in Medicine and Law Weekly, October 22nd, 2004

Alteon, Inc., (ALT) announced that it has been granted a patent on additional thiazolium compounds in the A.G.E. Crosslink Breaker class. A.G.E. Crosslink Breakers, a class of compounds discovered by Alteon, offer the possibility of the first therapeutic approach to treat and even reverse certain medical conditions related to aging and diabetes.

U.S. patent 6,790,859 "Reversing advanced glycosylation crosslinks using heterocyclic-substituted thiazolium compounds," was issued September 14, 2004.

These new compounds hold promise for reversing the deleterious aging of key proteins in the body. The patent claims cover their potential utility in treating...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2004-10-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry